Cerebrovascular accident
|
0.100 |
Biomarker
|
group |
BEFREE |
Liraglutide (LG) is a new kind of long-acting analogue of glucagon-like peptide-1 (GLP-1) and has potential protective effects in stroke.
|
31535381 |
2020 |
Cerebrovascular accident
|
0.100 |
Biomarker
|
group |
BEFREE |
GLP-1 agonists on the other hand, showed significant reduction in MACE (RR 0.92; 95% CI 0.87-0.97), death from CV causes (RR=0.88; 95% CI 0.80-0.97), and death from any cause (RR=0.89; 95% CI 0.82-0.96).
|
30713085 |
2019 |
Cerebrovascular accident
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The LEADER and SUSTAIN-6 trials evaluating the safety and efficacy of the GLP-1 analogs liraglutide and semaglutide, respectively, showed a statistically significant reduction in the primary outcome (major adverse cardiac events [MACE]: CV death, myocardial infarction, and stroke) and the secondary combined outcome when compared to placebo.
|
30767126 |
2019 |
Cerebrovascular accident
|
0.100 |
Biomarker
|
group |
BEFREE |
We searched the PubMed, Embase, and Google scholar databases, combining the term "glucagon-like peptide 1" OR "GLP-1" OR "incretin" OR "liraglutide" OR "exenatide" OR "lixisenatide" OR "dulaglutide" OR "albiglutide" AND "inpatient" OR "hospital" OR "perioperative" OR "postoperative" OR "surgery" OR "myocardial infarction" OR "stroke" OR "cerebrovascular disease" OR "transient ischaemic attack" OR "ICU" OR "critical care" OR "critical illness" OR "CCU" OR "coronary care unit."
|
31141838 |
2019 |
Cerebrovascular accident
|
0.100 |
Biomarker
|
group |
BEFREE |
Fasting GLP-1 was higher in the patients that suffered a stroke compared to healthy controls (25.1 vs. 18.0 pmol/L; p = 0.004).
|
31307484 |
2019 |
Cerebrovascular accident
|
0.100 |
Biomarker
|
group |
BEFREE |
GLP1-RA as a class reduce risk of ASCVD showing a significant reduction in MI and stroke.
|
30794833 |
2019 |
Cerebrovascular accident
|
0.100 |
Biomarker
|
group |
BEFREE |
In comparison, GLP-1 RA appear to preferentially reduce ischemic events (stroke or myocardial infarction) over hospitalization for heart failure, and demonstrated renoprotection in several of the CVOTs.
|
31436559 |
2019 |
Cerebrovascular accident
|
0.100 |
Biomarker
|
group |
BEFREE |
Shortly thereafter, the injectable glucagon-like peptide agonists (GLP-1) liraglutide and semaglutide found a significant reduction in composite major cardiovascular events (CV death, non-fatal MI, or stroke).
|
30406850 |
2018 |
Cerebrovascular accident
|
0.100 |
Biomarker
|
group |
BEFREE |
Previous research has demonstrated that GLP-1 analogs are neuroprotective in several neurological disease models including Alzheimer's disease (AD), Parkinson's disease (PD), and stroke.
|
29705602 |
2018 |
Cerebrovascular accident
|
0.100 |
Biomarker
|
group |
BEFREE |
Interestingly, gliptins can also improve stroke outcome in rodents independently from GLP1.
|
29776406 |
2018 |
Cerebrovascular accident
|
0.100 |
Biomarker
|
group |
BEFREE |
GLP-1-based therapies administered before, during or after experimental stroke in diabetic and non-diabetic animals were evaluated.
|
29411931 |
2018 |
Cerebrovascular accident
|
0.100 |
Biomarker
|
group |
BEFREE |
SGLT2i and GLP-1 RA may have a synergic effect on glucose reduction, weight reduction, renal impairment (both an independent lethal disease and a CVD risk factor) improvement, and cardiac event reduction, because the first reduces HF and related events and the second decreases CVD risk (mainly MI and stroke).
|
29865997 |
2018 |
Cerebrovascular accident
|
0.100 |
Biomarker
|
group |
BEFREE |
Recently, semaglutide, a GLP-1 analog, has been shown to significantly reduce stroke incidence in a randomized controlled trial.
|
28477558 |
2017 |
Cerebrovascular accident
|
0.100 |
Biomarker
|
group |
BEFREE |
No trial evaluating GLP-1-analogues reported data on stroke, microvascular complications or socioeconomic effects.
|
28489279 |
2017 |
Cerebrovascular accident
|
0.100 |
Biomarker
|
group |
BEFREE |
Proglucagon-derived peptides, especially glucagon-like peptide-1 (GLP-1) and its long-acting mimetics, have exhibited neuroprotective effects in animal models of stroke.
|
27856285 |
2017 |
Cerebrovascular accident
|
0.100 |
Biomarker
|
group |
BEFREE |
GLP-1 agonists did not affect the risk of MI (RR: 0.917; CI: 0.830-1.014; p = 0.092) as well as the risk of stroke (RR: 0.882; CI: 0.759-1.023; p = 0.097), HF (RR: 0.967; CI: 0.803-1.165; p = 0.725), retinopathy (RR: 1.000; CI: 0.807-1.238; p = 0.997) and nephropathy (RR: 0.866; CI: 0.625-1.199; p = 0.385).
|
29113708 |
2017 |